Market closedNon-fractional
PTC Therapeutics/PTCT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About PTC Therapeutics
PTC Therapeutics Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of orally administered, small-molecule therapeutics. Its target area is RNA biology post-transcriptional control processes of the events occurring in a cell when an RNA messenger is copied from DNA during the transcription process. The discovered products address multiple therapeutic areas, including rare disorders, such as nonsense mutations in Duchenne muscular dystrophy and oncology.
Ticker
PTCT
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
South Plainfield, United States
Employees
1,022
Website
www.ptcbio.com
PTC Therapeutics Metrics
BasicAdvanced
$2.6B
Market cap
-
P/E ratio
-$7.68
EPS
0.67
Beta
-
Dividend rate
Price and volume
Market cap
$2.6B
Beta
0.67
Financial strength
Current ratio
2.034
Quick ratio
1.896
Long term debt to equity
-225.609
Total debt to equity
-252.862
Interest coverage (TTM)
-1.82%
Management effectiveness
Return on assets (TTM)
-10.29%
Return on equity (TTM)
85.72%
Valuation
Price to revenue (TTM)
2.734
Price to book
-2.87
Price to tangible book (TTM)
-1.96
Price to free cash flow (TTM)
-12.711
Growth
Revenue change (TTM)
20.39%
Earnings per share change (TTM)
-2.77%
3-year revenue growth (CAGR)
29.16%
3-year earnings per share growth (CAGR)
4.74%
What the Analysts think about PTC Therapeutics
Analyst Ratings
Majority rating from 13 analysts.
PTC Therapeutics Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$210M
-31.56%
Net income
-$92M
-41.23%
Profit margin
-43.55%
-14.12%
PTC Therapeutics Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$2.66
-$1.76
-$2.06
-$1.20
-
Expected
-$1.24
-$1.17
$0.50
-$1.24
-$1.07
Surprise
113.71%
50.36%
-515.71%
-3.29%
-
PTC Therapeutics News
AllArticlesVideos
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
GlobeNewsWire·14 hours ago
PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2024 Financial Results
PRNewsWire·1 day ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
PRNewsWire·2 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for PTC Therapeutics stock?
PTC Therapeutics (PTCT) has a market cap of $2.6B as of July 27, 2024.
What is the P/E ratio for PTC Therapeutics stock?
The price to earnings (P/E) ratio for PTC Therapeutics (PTCT) stock is 0 as of July 27, 2024.
Does PTC Therapeutics stock pay dividends?
No, PTC Therapeutics (PTCT) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next PTC Therapeutics dividend payment date?
PTC Therapeutics (PTCT) stock does not pay dividends to its shareholders.
What is the beta indicator for PTC Therapeutics?
PTC Therapeutics (PTCT) has a beta rating of 0.67. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell PTC Therapeutics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.